What Sevenpoint One does

Sevenpoint One (세븐포인트원) is a South Korea-based digital healthcare company founded in 2017 that develops AI-powered and XR-based solutions for early dementia detection and cognitive health management. Its flagship product AlzWIN is a speech-based cognitive assessment that completes in approximately one minute, uses proprietary NLP and speech analysis algorithms trained on clinical trial data, and is certified under ISO 13485 and GMP for medical device quality. Its second product, SENTENTS, combines extended reality (XR) technology with cognitive behavioral therapy principles to deliver immersive therapeutic experiences aimed at reducing depression (reported 66.9% reduction) and increasing well-being (reported 86% happiness increase) among elderly users.

The company operates a B2B2C go-to-market model, distributing AlzWIN through healthcare institutions including memory clinics, dementia care centers, and occupational therapy practices, while SENTENTS is offered via healthcare and wellness partnerships. Sevenpoint One maintains a broad institutional partnership ecosystem in Korea spanning life insurance (Hanwha Life, Samsung Life), major hospitals (Asan Medical Center, Seoul National University Bundang Hospital), pharmaceutical companies (Eisai), technology platforms (Naver), and public health programs (Gyeonggi-do province). Revenue is generated through subscription/recurring arrangements with healthcare institutions, though specific pricing is not publicly disclosed. The company has a US sales/operations office in Seattle, Washington alongside its Korean headquarters in Seoul, and was recognized by AARP's AgeTech Collaborative in 2025 as one of six startups innovating in brain health.

With 11-50 employees, the company remains early-stage: total disclosed funding to date is approximately $187,472 (a 2021 round with CNTTECH, NAVER D2SF, and other Korean investors), supplemented by an undisclosed 2025 XLIMIT Accelerator participation. The company is privately held and founder-led, with no disclosed institutional investors beyond CNT Tech.

Name

Sevenpoint One

Legal name

주식회사 세븐포인트원 (Seven Point One Inc.)

Website

https://sevenptone.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Sevenpoint One is a South Korea-based digital healthcare company founded in 2017 that offers AlzWIN, an AI-powered one-minute speech-based cognitive assessment for early dementia detection, and SENTENTS, an XR-based therapeutic platform, sold through healthcare institutions, insurers, and public health partners.

Ownership category

akta.pro rank

Product category

Digital Health - Cognitive Assessment

NAICS

Services for the Elderly and Persons with Disabilities (62412)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

akta.pro secondary industries

Cognitive Stimulation & Reminiscence Therapy (Non-Clinical) (HSABAEAH), Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF)

Keywords

• Cognitive health assessment
• Dementia screening software
• Speech-based diagnostics
• XR mental health therapy
• Brain health platform

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. AlzWIN Cognitive Assessment Services: AI-powered speech-based cognitive assessment tool delivered to healthcare institutions and memory clinics. Healthcare providers administer the test to patients, with results used for early dementia detection and screening.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sevenpoint One develops and sells AlzWIN, an AI-powered one-minute speech-based cognitive assessment tool for early dementia detection, and SENTENTS, an XR-based therapy platform that uses cognitive behavioral therapy principles to reduce depression and improve well-being in elderly users. Both products are delivered to healthcare institutions and clinical partners under a B2B2C subscription model.

Product overview

Sevenpoint One offers a dual-product portfolio focused on digital brain health solutions. The core offerings are: (1) AlzWIN — an AI-powered speech-based cognitive assessment tool for rapid dementia screening, and (2) SENTENTS — an XR-based therapeutic platform for depression and cognitive decline prevention using cognitive behavioral therapy. Together, these products address the full spectrum from early detection (AlzWIN) to intervention and prevention (SENTENTS), enabling healthcare providers and individuals to manage brain health proactively.

Differentiator

Problem solved

Functional benefit

Brands

• AlzWIN: AI-powered cognitive assessment solution for rapid brain health screening and dementia detection. Offers one-minute speech-based testing with ISO 13485 and GMP quality certifications.
• SENTENTS

Products and services

• AlzWIN AI-powered cognitive health assessment solution that uses speech-based testing to evaluate brain health in approximately one minute. The solution is designed for accessibility for users aged 60 and above, with clinical validation for identifying cognitive decline and Alzheimer's disease. Distributed to memory clinics, dementia care centers, occupational therapy practices, and public health programs.
• SENTENTS XR-based solution combining extended reality technology with cognitive behavioral therapy principles to help users recall happy memories, reduce depression, and improve happiness in elderly users. Features real-time multi-playback functionality with elderly-friendly UI/UX design.

Quantifiable outcome

• 66.9% reduction in depression symptoms with SENTENTS XR therapy
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature2 records

Partnerships

Eight partnerships are on record, tiered core.

• AgeTech Collaborative from AARPcoreGTM or Marketing PartnerSeven Point One was selected as one of six startups to be spotlighted by the AgeTech Collaborative from AARP during Alzheimer's & Brain Awareness Month, highlighting innovative brain health solutions including AI-powered cognitive assessments and VR-based brain training.
• EisaicoreStrategic or Co-development PartnerCollaboration with Eisai, a pharmaceutical company, on brain health solutions. Eisai has developed dementia treatments including donanemab and lecanemab that align with Seven Point One's early diagnosis focus.
• Gyeonggi-docoreStrategic or Co-development PartnerPartnership with Gyeonggi-do province for healthcare services, utilizing AlzWIN for early dementia screening in public health programs.
• Seoul National University Bundang Hospital (SNUBH)coreStrategic or Co-development PartnerClinical collaboration with SNUBH for validation and adoption of cognitive assessment technology in hospital settings.
• Hanwha LifecoreStrategic or Co-development PartnerPartnership with Hanwha Life Insurance for brain health assessment integration with insurance and healthcare services.
• Samsung LifecoreStrategic or Co-development PartnerPartnership with Samsung Life Insurance for brain health assessment integration with insurance services.
• Asan Medical CentercoreStrategic or Co-development PartnerClinical collaboration with Asan Medical Center for validation and implementation of cognitive assessment technology.
• Korean Association of University Hospitals of Health and Welfare (CAUHS)coreStrategic or Co-development PartnerPartnership with university healthcare network for research and clinical implementation of brain health solutions.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Linus Health: Digital cognitive assessment platform using speech, AI, and digital biomarkers for early dementia detection. Highly comparable to AlzWIN in product category, target buyers (clinicians and health systems), and use case (screening for cognitive decline).
• Cogstate: Provides computerized cognitive assessment tools widely used in clinical trials, healthcare, and research. Directly comparable to AlzWIN as a digital cognitive testing platform serving healthcare and research customers.
• Cambridge Cognition: Developer of CANTAB cognitive assessment software for clinical trials, healthcare, and academic research. Comparable to AlzWIN in delivering validated, computerized cognitive assessments to clinicians and researchers.
• BrainCheck: Digital cognitive assessment platform used by clinicians for rapid screening and tracking of cognitive function. Closely comparable to AlzWIN in product (rapid cognitive screening) and target market (US-based clinicians and health systems).
• Altoida: AI-driven digital cognitive assessment platform with FDA clearance, focused on early detection of Alzheimer's and other neurodegenerative conditions. Comparable to AlzWIN in approach (AI-based digital assessment) and condition focus (Alzheimer's/dementia).
• Neurotrack: Digital cognitive health company offering screening and longitudinal monitoring for memory and cognitive decline. Comparable to AlzWIN in product positioning (digital screening for cognitive decline) and end-user focus (seniors concerned about memory).
• XRHealth: VR-based therapeutic platform for physical and cognitive rehabilitation, including conditions common in older adults. Comparable to SENTENTS in modality (extended reality therapy) and target population (patients with cognitive/behavioral conditions).
• BehaVR: VR-based digital therapeutics for mental and behavioral health, including anxiety and depression. Comparable to SENTENTS in using immersive XR experiences as a therapeutic modality for mental health outcomes.

Emerging players

• C2N Diagnostics: Diagnostics company focused on Alzheimer's disease detection via blood-based biomarkers (PrecivityAD). Adjacent peer to AlzWIN in the Alzheimer's early-diagnosis category but using a different (lab-based blood test) modality.

Broad incumbents

• Roche Diagnostics: Global diagnostics and pharmaceutical incumbent developing Elecsys Alzheimer's disease biomarkers and broader digital health initiatives. Comparable as a large incumbent in the Alzheimer's diagnostics and care pathway where Seven Point One is positioning.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/seven-point-one-inc

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sevenpoint One